Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial Carcinoma

The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Related Keywords

Ohio ,United States ,Cleveland ,Shilpa Gupta ,Genitourinary Medical Oncology At Taussig Cancer Institute ,Genitourinary Oncology Program At Cleveland Clinic ,Genitourinary Medical Oncology ,Taussig Cancer Institute ,Genitourinary Oncology Program ,Cleveland Clinic ,Enfortumab Vedotin Ejfv ,Pembrolizumab ,Ev 103 Trial ,Metastatic Urothelial Carcinoma ,Asco Annual Meeting ,